Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024
Operating activities
Net income	$ 241,198	$ 89,954
Adjustments to reconcile net income to net cash (used in) provided by operating activities:
Depreciation and amortization	2,062	2,694
Stock-based compensation expense	10,793	14,550
Impairment of out-license asset and remeasurement of CVR liability, net		6,772
Loss on debt extinguishment	10,286	12,630
Gain on Sale Transactions, net (Note 6)	(339,102)	(177,732)
Inventory write-downs, net		2,481
Change in fair value of derivatives	12,608	576
Other non-cash adjustments, net	2,490	(1,843)
Changes in operating assets and liabilities:
Trade receivables, net	106,161	85,217
Inventory	(18,474)	(18,557)
Prepaid manufacturing	396	7,170
Other prepaid, current and non-current assets	(869)	(4,249)
Accounts payable	833	40,077
Accrued rebates, fees and reserves	(68,053)	6,523
TSA related operating assets and liabilities, net	(10,547)	(4,781)
Accrued compensation	(7,329)	(2,643)
Accrued and other current and non-current liabilities	(14,911)	(45,871)
Net cash (used in) provided by operating activities	(72,458)	12,968
Investing activities
Purchases of investments in marketable securities	(20,726)
Proceeds from maturities of investments in marketable securities		6,200
Proceeds from sale of investments in marketable securities		8,688
Net cash received related to the Sale Transactions (Note 6)	478,681	227,823
Milestone payment to Junshi Biosciences	(12,500)	(12,500)
Other investing activities, net	(303)	208
Net cash provided by investing activities	445,152	230,419
Financing activities
Proceeds from (repayment of) Revenue Purchase and Sale Agreement, net of issuance costs	(47,652)	36,495
Proceeds from purchase under the employee stock purchase plan	188	685
Taxes paid related to net share settlement	(280)	(2,456)
Redemption of 2026 Convertible Notes, including transaction costs	(233,185)
Other financing activities, net	(859)	50
Net cash used in financing activities	(281,788)	(187,038)
Net increase in cash, cash equivalents and restricted cash	90,906	56,349
Cash, cash equivalents and restricted cash at beginning of period	126,250	103,343
Cash, cash equivalents and restricted cash at end of period	$ 217,156	159,692
Supplemental disclosures of non-cash activities
Non-cash employee bonuses settled in common stock		4,408
Financing issuance costs in accrued and other current liabilities		1,008
2027 Term Loans
Financing activities
Repayment of Term Loan, premiums and exit fees		(260,387)
2029 Term Loans
Financing activities
Proceeds from Term Loan, net of debt discount and issuance costs		37,120
ATM Offering
Financing activities
Proceeds from issuance of common stock, net of issuance costs		$ 1,455